Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report published by Infinium Global Research on the blepharitis drugs market provides an in-depth analysis of segments and
sub-segments in the global as well as regional blepharitis drugs market. The
study also highlights the impact of drivers, restraints, and macro indicators
on the global and regional blepharitis drugs market over the short term as well
as long term. The report is a comprehensive presentation of trends, forecast, and dollar values of the global blepharitis drugs market. According to the report,
the global blepharitis drugs market is projected to grow at a healthy CAGR over
the forecast period of 2020-2026.
Blepharitis is a chronic disorder that causes inflammation of the
eyelids. The rising population of blepharitis across the globe and the
emergence of drugs used in the treatment of risk related to blepharitis such as
blepharoconjunctivitis, hordeolum, and chalazion (Styes) are the key factors to
boost the market growth. Additionally, the current concern over the spread of
coronavirus is also projected to have a negative impact on the blepharitis
drugs market for the short term. Numerous countries, comprising major
pharmaceutical industry, have initiated lockdowns and enforced nationwide
travel and trade restrictions. The main factors expected to exert an impact on
the blepharitis drugs market include delay in outpatient hospital visits for
non-urgent treatments, reduced pharmaceutical spending, and delay in approval
and launch of new drugs, and supply chain disruptions worldwide. On the other
hand, the impact is somewhat being neutralized by the shift of healthcare
providers and patients towards teleconsultation and telemedicine and has led to
an increase in the number of virtual visits internationally.
The global blepharitis drugs market is primarily driven by
increasing prevalence of ophthalmological disorders, such as dry eye, uveitis
among others. Furthermore, factors such as growing demand for advanced
treatment, government initiatives, rising awareness among mass regarding eye
care, and increasing market players offering newer products for the treatment
of blepharitis are likely to propel the market growth. Moreover, the
involvement of leading players in new product development and enhancing their
existing products to increase their product portfolio is heightening the growth
of the global blepharitis drugs market. In addition, the usage of a combination
of off-label steroids and antibiotics is growing to treat blepharitis because
of the deficiency of availability of approved therapies and their proven
advantages over monotherapy. Consequently, vendors are recording increased
sales, which will contribute to the growth of the blepharitis drug market over
the projection period. Conversely, the development of novel treatment
procedures, antimicrobial resistance, and a dearth of approved therapies to
treat blepharitis may hinder the growth of the blepharitis drugs market in the
near future.
Among the geographies, North America region is expected to hold
the largest share in the global blepharitis drugs market owing to a surge in
funding for the development of research and health care infrastructure.
Further, factors such as an increase in the incidence of ocular diseases such
as blepharitis and early phase diagnosis and treatment of diseases are driving
the biotechnology & pharmaceutical division in the region, which, in turn,
is anticipated to propel the blepharitis drugs market in North America
region. Furthermore, the Asia Pacific region is projected to witness the the fastest growth in the blepharitis drugs market during the forecast period owing
to the rising prevalence of eye disorders. In addition, the rising awareness
about the health and increasing demand for healthcare facilities in emerging
economies such as China and India drive the market in this region.
The report on global blepharitis drugs market covers segments such
as type, treatment type, dosage form, route of administration, and end- users.
On the basis of type, the sub-markets include anterior blepharitis, and
posterior blepharitis. On the basis of treatment type, the sub-markets include
warm compresses or eyelid scrubs, mechanical glandular eyelid massage,
artificial lubricants, topical antibiotics, topical corticosteroids,
combination topical corticosteroids and antibiotic, meibomian gland expression,
oral antibiotics, and dietary supplements. On the basis of dosage form, the
sub-markets include tablets, solution, suspension, ointment, and others. On the
basis of route of administration, the sub-markets include oral, and topical. On
the basis of end- users, the sub-markets include hospitals, homecare, specialty
clinics, and others.
The report provides profiles of the companies in the market such
as AbbVie Inc., Amgen Inc, Celgene Corporation, Pfizer Inc., Biogen, Novartis
AG, Johnson & Johnson Services, Inc., Merck & Co., Inc., Regeneron
Pharmaceuticals Inc., and Gilead Sciences, Inc.
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report
provides insights into the factors that are driving and restraining the growth
in this market. Moreover, The IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of the blepharitis
drugs market. Moreover, the study highlights current market trends and provides
forecast from 2020-2026. We also have highlighted future trends in the market
that will affect the demand during the forecast period. Moreover, the
competitive analysis given in each regional market brings an insight into the
market share of the leading players.
Please Choose One of them.